Evidence map›Paper›PMID 42764984›Full record

ArticleMolecular therapy. Advances2026

Automated zonal-rotor CsCl ultracentrifugation with ÄKTA-based fractionation removes empty and intermediate AAV capsids.

Kosuke Horita, Ryuki Miyauchi, Hideaki Yamamoto, Yasuhiro Yamazaki, Kentaro Nagatomo, Takahide Aburatani, Shuji Takeda, Satoshi Baba

Abstract read
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kosuke HoritaModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 140-8710, Japan.
Ryuki MiyauchiModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 140-8710, Japan.
Hideaki YamamotoModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 140-8710, Japan.
Yasuhiro YamazakiModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 140-8710, Japan.
Kentaro NagatomoModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 140-8710, Japan.
Takahide AburataniModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 140-8710, Japan.
Shuji TakedaModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 140-8710, Japan.
Satoshi BabaModality Research Laboratories II, Daiichi Sankyo Co., Ltd., Shinagawa, Tokyo 140-8710, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant adeno-associated virus (AAV) preparations contain heterogeneous full, empty, and intermediate capsids. Although anion-exchange chromatography is scalable, it does not always resolve these populations, particularly intermediate capsids. A workflow integrated zonal-rotor cesium chloride (CsCl) density-gradient ultracentrifugation with ÄKTA-based loading, inline monitoring, unloading, and fraction collection. SW41Ti swing-bucket experiments defined the empirical 1,240-1,360 mg/cm

Indexed as

adeno-associated viruscesium chlorideempty capsidintermediate capsidultracentrifugationzonal rotor

Identifiers

PMID42764984
PMCPMC13590079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.